PharmaLytica 2021 Hyderabad review.

Data breach prompts Dr Reddy's to shut key plants

October 22, 2020

Shares of the pharma company, which has a partnership to run clinical trials of Russia’s Sputnik-V COVID-19 vaccine in India, fell as much as 4.3% on the news, dragging the Nifty pharma sub-index down 2%. A data breach at Dr Reddy’s Laboratories Ltd prompted the Indian drugmaker to shut its key plants globally, television channel ET Now reported on Thursday, citing sources.

The data breach occurred at servers of the company and plants in the United States, United Kingdom, Brazil, India and Russia were impacted, the ET Now report said.

Dr Reddy’s did not immediately respond to any queries. The Russian Direct Investment Fund (RDIF) and Dr Reddy’s got renewed approval to conduct late-stage clinical trials in India for the Sputnik-V vaccine after the country’s regulator had earlier asked them to conduct a smaller trial.


This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More